Asset
IKT-001PRO
INHIBIKASE THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05623774 | phase1 | completed | 2022-12-16 | 2024-06-30 | Inhibikase Therapeutics | A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg |
| NCT06643143 | phase2 | withdrawn | 2025-06-30 | 2027-06-30 | Inhibikase Therapeutics | A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) |
| NCT07365332 | phase3 | recruiting | 2026-04-23 | 2029-06-01 | Inhibikase Therapeutics | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) |
| NCT07632898 | phase3 | not_yet_recruiting | 2026-10-23 | 2030-06-30 | Inhibikase Therapeutics | Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) |
FDA applications (0)
This company has no applications containing this asset.